<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Arovella Therapeutics Ltd — News on 6ix</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd</link>
<description>Latest news and press releases for Arovella Therapeutics Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 01 Apr 2026 03:15:04 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/arovella-therapeutics-ltd" rel="self" type="application/rss+xml" />
<item>
<title>CLDN18.2 CAR iNKT Cell Preclinical Data Update</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/cldn182-car-inkt-cell-preclinical-data-update</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/cldn182-car-inkt-cell-preclinical-data-update</guid>
<pubDate>Wed, 01 Apr 2026 03:15:04 GMT</pubDate>
<description>CLDN18.2 CAR iNKT Cell Preclinical Data Update</description>
</item>
<item>
<title>Half Year Report and Appendix 4D</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/half-year-report-and-appendix-4d-2</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/half-year-report-and-appendix-4d-2</guid>
<pubDate>Thu, 19 Feb 2026 09:18:03 GMT</pubDate>
<description>Half Year Report and Appendix 4D</description>
</item>
<item>
<title>ALA's IND FOR ALA-101 ACCEPTED BY THE U.S.FDA</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/alas-ind-for-ala-101-accepted-by-the-usfda</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/alas-ind-for-ala-101-accepted-by-the-usfda</guid>
<pubDate>Thu, 29 Jan 2026 03:32:07 GMT</pubDate>
<description>ALA's IND FOR ALA-101 ACCEPTED BY THE U.S.FDA</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-57</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-57</guid>
<pubDate>Fri, 23 Jan 2026 03:12:04 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>Positive FDA Type D Meeting Outcome</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/positive-fda-type-d-meeting-outcome</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/positive-fda-type-d-meeting-outcome</guid>
<pubDate>Tue, 28 Oct 2025 02:07:06 GMT</pubDate>
<description>Positive FDA Type D Meeting Outcome</description>
</item>
<item>
<title>CLDN18.2 CAR-T cells eliminate pancreatic cancer cells</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/cldn182-car-t-cells-eliminate-pancreatic-cancer-cells</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/cldn182-car-t-cells-eliminate-pancreatic-cancer-cells</guid>
<pubDate>Thu, 02 Oct 2025 04:08:15 GMT</pubDate>
<description>CLDN18.2 CAR-T cells eliminate pancreatic cancer cells</description>
</item>
<item>
<title>Arovella receives R&D tax rebate of $3.21 million</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/arovella-receives-randd-tax-rebate-of-dollar321-million</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/arovella-receives-randd-tax-rebate-of-dollar321-million</guid>
<pubDate>Tue, 23 Sep 2025 03:31:08 GMT</pubDate>
<description>Arovella receives R&D tax rebate of $3.21 million</description>
</item>
<item>
<title>S&P DJI Announces September 2025 Quarterly Rebalance</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/sandp-dji-announces-september-2025-quarterly-rebalance-81</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/sandp-dji-announces-september-2025-quarterly-rebalance-81</guid>
<pubDate>Fri, 05 Sep 2025 11:28:14 GMT</pubDate>
<description>S&P DJI Announces September 2025 Quarterly Rebalance</description>
</item>
<item>
<title>Appendix 4E and Annual Report</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/appendix-4e-and-annual-report-66</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/appendix-4e-and-annual-report-66</guid>
<pubDate>Fri, 22 Aug 2025 03:11:54 GMT</pubDate>
<description>Appendix 4E and Annual Report</description>
</item>
<item>
<title>S&P DJI Announces March 2025 Quarterly Rebalance</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/sandp-dji-announces-march-2025-quarterly-rebalance-96</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/sandp-dji-announces-march-2025-quarterly-rebalance-96</guid>
<pubDate>Fri, 07 Mar 2025 11:22:14 GMT</pubDate>
<description>S&P DJI Announces March 2025 Quarterly Rebalance</description>
</item>
<item>
<title>Research Agreement with University of North Carolina</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/research-agreement-with-university-of-north-carolina</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/research-agreement-with-university-of-north-carolina</guid>
<pubDate>Mon, 03 Mar 2025 06:55:08 GMT</pubDate>
<description>Research Agreement with University of North Carolina</description>
</item>
<item>
<title>Reinstatement to Official Quotation</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/reinstatement-to-official-quotation-67</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/reinstatement-to-official-quotation-67</guid>
<pubDate>Wed, 26 Feb 2025 04:37:15 GMT</pubDate>
<description>Reinstatement to Official Quotation</description>
</item>
<item>
<title>Prospectus</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/prospectus-32</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/prospectus-32</guid>
<pubDate>Wed, 26 Feb 2025 04:36:05 GMT</pubDate>
<description>Prospectus</description>
</item>
<item>
<title>Arovella $15m Placement to fund Phase 1</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/arovella-dollar15m-placement-to-fund-phase-1</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/arovella-dollar15m-placement-to-fund-phase-1</guid>
<pubDate>Wed, 26 Feb 2025 04:36:05 GMT</pubDate>
<description>Arovella $15m Placement to fund Phase 1</description>
</item>
<item>
<title>Voluntary Suspension</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/voluntary-suspension-18</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/voluntary-suspension-18</guid>
<pubDate>Mon, 10 Feb 2025 04:01:06 GMT</pubDate>
<description>Voluntary Suspension</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/trading-halt-505</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/trading-halt-505</guid>
<pubDate>Thu, 06 Feb 2025 03:44:14 GMT</pubDate>
<description>Trading Halt</description>
</item>
<item>
<title>Arovella $20m Placement - fully funded to complete Phase 1</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/arovella-dollar20m-placement-fully-funded-to-complete-phase-1</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/arovella-dollar20m-placement-fully-funded-to-complete-phase-1</guid>
<pubDate>Fri, 10 Jan 2025 03:59:16 GMT</pubDate>
<description>Arovella $20m Placement - fully funded to complete Phase 1</description>
</item>
<item>
<title>Arovella receives R&D tax rebate of $3.0 million</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/arovella-receives-randd-tax-rebate-of-dollar30-million</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/arovella-receives-randd-tax-rebate-of-dollar30-million</guid>
<pubDate>Fri, 25 Oct 2024 04:16:05 GMT</pubDate>
<description>Arovella receives R&D tax rebate of $3.0 million</description>
</item>
<item>
<title>Positive pre-IND feedback from FDA for ALA-101</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/positive-pre-ind-feedback-from-fda-for-ala-101</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/positive-pre-ind-feedback-from-fda-for-ala-101</guid>
<pubDate>Wed, 07 Aug 2024 03:42:17 GMT</pubDate>
<description>Positive pre-IND feedback from FDA for ALA-101</description>
</item>
<item>
<title>Zolpimist Update</title>
<link>https://6ix.com/company/arovella-therapeutics-ltd/news/zolpimist-update</link>
<guid isPermaLink="true">https://6ix.com/company/arovella-therapeutics-ltd/news/zolpimist-update</guid>
<pubDate>Thu, 13 Jun 2024 02:47:17 GMT</pubDate>
<description>Zolpimist Update</description>
</item>
</channel>
</rss>